These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26296199)

  • 21. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.
    Noyes K; Liu H; Li Y; Holloway R; Dick AW
    Mov Disord; 2006 Mar; 21(3):362-72. PubMed ID: 16211621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine.
    Dave S; Weintraub D; Aarsland D; Ffytche DH
    Mov Disord Clin Pract; 2020 Jan; 7(1):32-36. PubMed ID: 31970209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuropsychiatric manifestations in Parkinson's disease].
    Oikonomou E; Paparrigopoulos T
    Psychiatriki; 2015; 26(2):116-30. PubMed ID: 26197101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What are the issues facing Parkinson's disease patients at ten years of disease and beyond? Data from the NPF-QII study.
    Hassan A; Wu SS; Schmidt P; Malaty IA; Dai YF; Miyasaki JM; Okun MS
    Parkinsonism Relat Disord; 2012 Dec; 18 Suppl 3():S10-4. PubMed ID: 22776044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson's Disease Psychosis.
    Rajagopalan K; Rashid N; Yakkala V; Doshi D
    Clinicoecon Outcomes Res; 2024; 16():149-159. PubMed ID: 38495124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychosis in Parkinson's disease: From the soft signs to the hard science.
    Lenka A; Herath P; Christopher R; Pal PK
    J Neurol Sci; 2017 Aug; 379():169-176. PubMed ID: 28716235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.
    Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A
    Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Koneru V; Espay AJ; Cole AJ; Weintraub D; Crist K; Pascual MB; Ondo WG
    Mov Disord; 2023 Nov; 38(11):1982-1987. PubMed ID: 37937768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The experience of care partners of patients with Parkinson's disease psychosis.
    Mantri S; Klawson E; Albert S; Rapoport R; Precht C; Glancey S; Daeschler M; Mamikonyan E; Kopil CM; Marras C; Chahine LM
    PLoS One; 2021; 16(3):e0248968. PubMed ID: 33740031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.
    Combs BL; Cox AG
    Neuropsychiatr Dis Treat; 2017; 13():737-744. PubMed ID: 28331324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Genetic Analysis of Psychosis in Parkinson's Disease.
    Radojević B; Dragašević-Mišković NT; Marjanović A; Branković M; Dobričić V; Milovanović A; Tomić A; Svetel M; Petrović I; Jančić I; Stanisavljević D; Savić MM; Kostić VS
    J Parkinsons Dis; 2021; 11(4):1973-1980. PubMed ID: 34151861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burden and health-related quality of life among caregivers of Brazilian Parkinson's disease patients.
    Carod-Artal FJ; Mesquita HM; Ziomkowski S; Martinez-Martin P
    Parkinsonism Relat Disord; 2013 Nov; 19(11):943-8. PubMed ID: 23831481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of Parkinson's disease-induced psychosis in a large U.S. managed care population.
    Holt RJ; Sklar AR; Darkow T; Goldberg GA; Johnson JC; Harley CR
    J Neuropsychiatry Clin Neurosci; 2010; 22(1):105-10. PubMed ID: 20160217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson's Disease Psychosis.
    Rashid N; Shim A; Andes S; Quale S; Abler V
    J Appl Gerontol; 2022 Jan; 41(1):198-206. PubMed ID: 33504252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating rates of reporting symptoms of Parkinson's disease psychosis: provider versus targeted questionnaire.
    Greger J; Aladeen T; Rainka M; Kale A; Capote H
    Int J Neurosci; 2022 May; 132(5):459-465. PubMed ID: 32910866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does an association between cigarette smoking and Parkinson's Disease-related psychosis exist? Insights from a large non-demented cohort.
    Terravecchia C; Mostile G; Rascunà C; Arabia G; Barone P; Marconi R; Morgante L; Quattrone A; Nicoletti A; Zappia M
    J Neurol Sci; 2021 Aug; 427():117509. PubMed ID: 34082149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mangone G; Tosin MHS; Goetz CG; Stebbins GT; Mestre TA
    Mov Disord; 2024 Mar; 39(3):560-570. PubMed ID: 38291860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease.
    Kaltenboeck A; Johnson SJ; Davis MR; Birnbaum HG; Carroll CA; Tarrants ML; Siderowf AD
    Parkinsonism Relat Disord; 2012 May; 18(4):321-6. PubMed ID: 22177623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
    Weintraub D; Comella CL; Horn S
    Am J Manag Care; 2008 Mar; 14(2 Suppl):S40-8. PubMed ID: 18402507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.